NEUROFIBROMA, PLEXIFORM
Clinical trials for NEUROFIBROMA, PLEXIFORM explained in plain language.
Never miss a new study
Get alerted when new NEUROFIBROMA, PLEXIFORM trials appear
Sign up with your email to follow new studies for NEUROFIBROMA, PLEXIFORM, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Promising drug may shrink inoperable tumors in kids with rare genetic condition
Disease control OngoingThis study tests a drug called selumetinib in children and young adults (ages 3-18) with neurofibromatosis type 1 (NF1) who have nerve tumors that cannot be removed by surgery. The goal is to see if the drug can shrink or slow the growth of these tumors. Participants take the dru…
Matched conditions: NEUROFIBROMA, PLEXIFORM
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New study tracks Selumetinib's Real-World impact on kids with NF1 tumors
Disease control OngoingThis study follows about 80-100 Chinese children aged 3-16 with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas. All participants take the drug selumetinib (Koselugo) and are monitored for 24 months to see how well it works and what side ef…
Matched conditions: NEUROFIBROMA, PLEXIFORM
Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New hope for NF1 patients: targeted drug shrinks inoperable tumors in early trial
Disease control OngoingThis study tests a drug called selumetinib in 32 Chinese children and adults with neurofibromatosis type 1 (NF1) who have nerve tumors that cannot be surgically removed. The goal is to check the drug's safety and how well it works at shrinking these tumors. Participants take the …
Matched conditions: NEUROFIBROMA, PLEXIFORM
Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC